Solar Foods raises €8m in Series B financing
Finnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant.
Germany boosts protein transition with €38m
The Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year.<br /><br />
Microharvest GmbH launches SCP-Pilot plant in Lissabon
German precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day.
AMR: Partnership set to improve in vivo antibiotics testing
The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.
VectorY Therapeutics raises €129m in Series A round
<p itemprop="headline">Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.</p>
ViaNautis Bio Ltd closes US$25m Series A financing
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
Recordbreaking BIO-Europe in Munich, but: back to 2019
The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already […]
Amyl Therapeutics bags �11m Series A extension
Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a �11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. <br /> <br /><br […]
Evotech screens cancer candidates for Dewpoint Therapeutics
German Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology.<br /><br />
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.